Gene · 6335
SCN9A: sodium voltage-gated channel alpha subunit 9
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SCN9A: sodium voltage-gated channel alpha subunit 9. Genes, record 6335. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6335
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15858 | Sodium channel protein type 9 subunit alpha | 1,988 | 43 | Ensembl, GeneID, HGNC |
Source UniProt
Patents50
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026517682 A | 2026-06-02 | 1 | Q15858 | Espacenet |
| EP 4698233 A2 | 2026-02-25 | 1 | Q15858 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 63910 | Q15858 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3845 | Q15858 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3851 | Q15858 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3851 | Q15858 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3845 | Q15858 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 35309 | Q15858 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 35312 | Q15858 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 35309 | Q15858 | Espacenet |
1 to 10 of 50
See all 50 patentsDrugs90
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ARTICAINE | CHEMBL1093 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| ARTICAINE HYDROCHLORIDE | CHEMBL1200819 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| AZD3161 | CHEMBL3545208 | Sodium channel protein type IX alpha subunit blocker | BLOCKER | ChEMBL |
| BENOXINATE | CHEMBL1200 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| BENOXINATE HYDROCHLORIDE | CHEMBL1200654 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CARBAMAZEPINE | CHEMBL108 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CENOBAMATE | CHEMBL3989949 | Sodium channel alpha subunit inhibitor | INHIBITOR | ChEMBL |
| CHLOROPROCAINE | CHEMBL1179047 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CHLOROPROCAINE HYDROCHLORIDE | CHEMBL944 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| COCAINE | CHEMBL370805 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
1 to 10 of 90
See all 90 drugsTrials1,313
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07599800 | LIDOCAINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07592143 | LIDOCAINE | PHASE3 | ClinicalTrials.gov | |
| NCT07588750 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT07572994 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07568496 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07547371 | ARTICAINE HYDROCHLORIDE | ClinicalTrials.gov | ||
| NCT07546370 | PRILOCAINE | PHASE4 | ClinicalTrials.gov | |
| NCT07546370 | LIDOCAINE | PHASE4 | ClinicalTrials.gov | |
| NCT07536594 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07511400 | LIDOCAINE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 1,313
See all 1,313 trialsNIH grants1,318
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SCN9A papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001863 | Yale Clinical and Translational Science Award | 19 | 2025 |
| R01NS034509 | Functional Genetics of the Neuronal Sodium Channel Gene SCN8A | 9 | 2025 |
| R35NS105076 | Unravelling Mechanisms and Novel Therapeutic Targets for Peripheral Neuropathy and Neuropathic Pain | 8 | 2025 |
| I50RX002999 | Center for Restoration of Nervous System Function | 7 | 2025 |
| R01AR060364 | Molecular Pathways of Pain Generation in Osteoarthritis | 5 | 2025 |
| R01HL112808 | Structural Basis for Antiarrhythmic Drug Action | 5 | 2025 |
| R01NS045594 | Study of Activity-Dependent Sympathetic Sprouting | 5 | 2025 |
| U19NS130608 | Human Nociceptor and Spinal Cord Molecular Signature Center | 5 | 2025 |
| UL1TR002345 | Washington University Institute of Clinical and Translational Sciences | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,318Source NIH's project files
See all 1,318 nih grantsPapers3,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Establishment of a human pluripotent stem cell-derived sensory neuron platform for studying diabetes-associated metabolic and oxidative stress-induced neuronal injury. | J Neurosci Methods | 2027 | 42826868 | PubTator, text mining | PubMed |
| Discovery and Characterization of Neuroactive Secondary Metabolites from Acacia sieberiana with Potential Analgesic Properties. | ACS Omega | 2026 | 42819829 | PubTator, text mining | PubMed |
| Peripheral NaV1.7 modulation reveals divergent peripheral and central adaptations in persistent trigeminal pain. | bioRxiv | 2026 | 42818013 | PubTator, text mining | PubMed |
| Chasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief? | Medicina (Kaunas) | 2026 | 42796305 | PubTator, text mining | PubMed |
| Pharmacological modulation of peripheral nerve excitability: a novel way to investigate sodium channel subtypes in humans. | Pain | 2026 | 42751727 | PubTator, text mining | PubMed |
| Deeper delving Nav1.8 inhibitor Suzetrigine in chronic pain. | Acta Pharmacol Sin | 2026 | 42745014 | PubTator, text mining | PubMed |
| Investigating genetic susceptibility to concussion through rare variants in ion channel and neurotransmission genes. | J Neurol | 2026 | 42730919 | PubTator, text mining | PubMed |
| Ion-Channel Activity of Characteristic Alkaloids From Uncaria rhynchophylla. | Chem Biodivers | 2026 | 42720106 | PubTator, text mining | PubMed |
| Antigen-Detected NMR for Minimal Epitope Engineering and Structure-Guided Selection of a NaV1.7-Selective Nanobody. | Adv Sci (Weinh) | 2026 | 42702812 | PubTator, text mining | PubMed |
| Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes. | Eur J Pain | 2026 | 42695143 | PubTator, text mining | PubMed |
1 to 10 of 3,231
See all 3,231 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6335
GET https://conductscience.org/api/genes/v1/6335/patents?page=2